# HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

> **NCT06737913** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 76 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma (HCC)

## Interventions

- **PROCEDURE:** HAI Adebrelimab
- **DRUG:** intravenous infusion (IV) of Adebrelimab (ADE)
- **DRUG:** intravenous infusion (IV) of Bevacizumab (Bev.)
- **PROCEDURE:** HAIC with FOLFOX regimen
- **DRUG:** Adebrelimab and bevacizumab maintainance treatment

## Key facts

- **NCT ID:** NCT06737913
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-03
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06737913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06737913, "HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06737913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*